Allergan PLC
Chicago, Illinois
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk


Abbvie scored 100 on the 2023-2024 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, the company increases the risk of dividing employees, alienating customers and harming shareholders. The company provides a benefits package for employees which covers transgender medical procedures for covered employees and dependents, including children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Abbvie forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Abbvie and Allergen’s CEO signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. Allergen is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism over traditional shareholder obligations. Abbvie is a member of the MCCA, indicating its focus on recruiting, retaining, and promoting employees based on race. The company is a Copper sponsor of Out & Equal and is a corporate partner of the NGLCC. AbbVie supports the Equality Act and donated to the Equality PAC. For these reasons, AbbVie receives a High Risk rating.

View Full Report

Board Bias

Expand Summary

CEO of AbbVie

Richard A. Gonzalez

Richard A. Gonzalez


Headquartered in Chicago, Illinois, AbbVie is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Richard A. Gonzalez and Richard A. Gonzalez serve as CEO/President and Chairman, respectively, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $101,550 to Republican causes and $84,950 to Democratic causes. Under their tenure, AbbVie currently holds a 'High Risk' risk rating.

View Full Board Bias Report

Political Contributions of Leadership:





Shareholder Proposals

Expand Summary

ESG Category
Summary of ResolutionMgmt RecTotal Vote % in Favor
5/5/23GovernanceJohn CheveddenSimple Majority VotingAgainst53.90%
5/5/23GovernanceDana Investment AdvisersIssue a Report on LobbyingAgainst35.70%
5/5/23GovernanceFriends Fiduciary CorporationIssue a Report on Patent ProcessAgainst29.00%
5/5/23GovernanceAs You SowReport on Political SpendingAgainst14.90%
5/6/22GovernanceKenneth SteinerShareholder Ratification of Termination Pay Exceeding 2.99x Total PayAgainst50.10%
5/6/22SocialAs You SowReport on Political SpendingAgainst39.32%
5/6/22GovernanceFriends Fiduciary Corp.Board Oversight of Risks Related to Anticompetitive PracticesAgainst32.82%
5/6/22GovernanceRhode Island Employees Retirement SystemIndependent Board ChairAgainst30.18%
Generate Reports